May 16, 2023 / 06:30PM GMT
Jon Wolleben - JMP Securities - Analyst
Good afternoon, everybody. Thanks for joining us. Jon Wolleben, senior analyst at JMP. We're pleased to have BioCryst Pharmaceuticals with us today, CEO, Jon Stonehouse, and Chief Development Officer and Chief R&D Officer, Helen Thackray. So, thanks, guys.
Questions and Answers:
Jon Wolleben - JMP Securities - AnalystWe're going to really touch on a little bit everything today. So I think what most people ask me about and probably ask you about is ORLADEYO to start, and maybe if you can give us an update, we just had the first quarter numbers, you reiterated your guidance for at least $220 million in sales. Tell us, how the early year progress and how things are tracking so for.
Jon Stonehouse - BioCryst Pharmaceuticals, Inc. - President & CEO
Sure. Thanks, Jon, for having us here. I don't know if I thought I'd say this, but good to be back in New York again, and to be in person. Helen and I are going to be making some forward-looking statements and those
Trustpilot
